Impax and Watson challenge Genzyme's Renvela patent

USA-based generic drugmaker Impax Laboratories has confirmed initiation of a challenge of a patent listed by Genzyme in connection with Renvela (sevelamer carbonate for suspension), 2.4g and 0.8g.

Impax said it filed its Abbreviated New Drug Application containing a Paragraph IV certification for a generic version of Renvela with the US Food & Drug Administration. Following receipt of the notice from the FDA that Impax' ANDA had been accepted for filing, Impax notified Genzyme, the New Drug Application holder and patent owner of its action.

Genzyme files patent infringement law suits